Learn more

PAMGENE BV

Overview
  • Total Patents
    154
  • GoodIP Patent Rank
    130,513
  • Filing trend
    0.0%
About

PAMGENE BV has a total of 154 patent applications. It increased the IP activity by 0.0%. Its first patent ever was published in 1998. It filed its patents most often in EPO (European Patent Office), WIPO (World Intellectual Property Organization) and United States. Its main competitors in its focus markets chemical engineering, biotechnology and measurement are TAKENAKA SHIGEORI, MWG BIOTECH AG and SHAFER DAVID A.

Patent filings per year

Chart showing PAMGENE BVs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Van Beuningen Marinus Gerardus 44
#2 Ruijtenbeek Robby 34
#3 De Wijn Richard 19
#4 Hilhorst Maria Helena 17
#5 Blok Herman Jacobus 14
#6 Van Damme Hendrik Sibolt 14
#7 Ingham Colin John 14
#8 Boender Pieter Jacob 11
#9 Beuningen Marinus Gerardus Joh 9
#10 Wu Ying 9

Latest patents

Publication Filing date Title
WO2021043953A1 Kinase activity signatures for predicting the response of non-small-cell lung carcinoma patients to a pd-1 or pd-l1 immune checkpoint inhibitor
EP3665301A1 Method for predicting the response of non-small-cell lung carcinoma patients to a medicament
WO2017167942A1 Method for predicting the response of melanoma patients to a medicament
EP3757223A1 Method for predicting the response of melanoma patients to a medicament
EP3298160A1 Method for predicting the response of melanoma patients to targeted pharmacotherapy
WO2016162451A1 A multi-layer cold specimen transport container without active cooling.
WO2014079927A1 Method and system for snap freezing tissues
WO2013037972A1 Method for predicting response to endocrine therapy
WO2012159997A1 Modified tyrosine amino acids, peptides containing them, and their use for detecting hydrolase enzyme activity
WO2012131065A1 Diagnosis, prognosis and treatment of scirrhous gastric cancer
WO2012049329A1 Method for predicting tyrosine kinase inhibitor (tki) resistance in patients suffering from chronic myelogenous leukemia (cml)
EP2417265A2 Method for predicting the response of locally advanced rectal cancer to chemoradiotherapy
EP2279262A2 Measurement of protein kinase activity in cerebrospinal fluid for diagnosis of neurological and psychiatric disorders
EP2243481A1 Irak kinase family as novel drug target for Alzheimer
EP2239570A1 Method for determining the estrogen receptor status of breast cancer
EP2239571A1 Method for profiling drug compounds using protein kinase inhibitors
EP2239578A1 Method for determining the survival prognosis of patients suffering from non-small cell lung cancer (NSCLC)
EP2239579A1 Method for the predicting of the response of non-small cell lung cancer patients to targeted pharmacotherapy
EP2239572A1 Method for the diagnosing and/or typing renal cell carcinoma
WO2009125020A1 Method for profiling drug compounds